Gilead Sciences’ Ranexa ranolazine has reduced angina frequency in the phase 4 type 2 diabetes evaluation of ranolazine in a study on subjects with chronic stable angina (TERISA), which was conducted on chronic angina patients with type 2 diabetes.

The study reports that the addition of ranolazine to background antianginal therapy reduced angina frequency as compared to placebo and background antianginal therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The TERISA study lead author, St. Luke’s Mid America Heart Institute cardiologist and the University of Missouri associate professor of medicine Mikhail Kosiborod said that there is a need for effective therapeutic strategies against angina in patients with diabetes.

"Although the safety and efficacy profile of ranolazine is well established, this is the first study to prospectively evaluate the antianginal effectiveness of ranolazine in patients with chronic angina and concurrent type 2 diabetes," Kosiborod added.

"The study reports that the addition of ranolazine to background antianginal therapy reduced angina frequency as compared to placebo and background antianginal therapy."

Subsequent to a single-blind, four-week placebo run-in phase, 927 patients were randomised with ranolazine or a corresponding placebo besides background antianginal therapy for eight weeks.

See Also:

The number of angina episodes and sublingual nitroglycerin doses taken by patients on a daily basis has been documented using an electronic diary.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the data, the average weekly angina frequency was considerably lower with ranolazine against placebo, as was weekly sublingual nitroglycerin use.

The study noted a similar serious adverse event profile and discontinuation rate due to adverse events between the ranolazine and placebo groups.

Non-serious adverse events include nausea, dizziness and constipation.